These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6744035)

  • 1. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats.
    Lemeignan M; Millart H; Lamiable D; Molgo J; Lechat P
    Brain Res; 1984 Jun; 304(1):166-9. PubMed ID: 6744035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-performance liquid chromatographic determination of 4-aminopyridine and 3,4-diaminopyridine in rat cerebrospinal fluid and serum.
    Lamiable D; Millart H
    J Chromatogr; 1983 Jan; 272(1):221-5. PubMed ID: 6841545
    [No Abstract]   [Full Text] [Related]  

  • 3. Equipotency of anti-curare activity of 4-aminopyridine and 3,4-diaminopyridine in anesthetized rats.
    Uchiyama T; Lemeignan M; Lechat P
    Jpn J Pharmacol; 1985 Jul; 38(3):329-33. PubMed ID: 2997528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of 4-aminopyridine with [3H]phencyclidine receptors in rat brain homogenates.
    Lai WS; el-Fakahany EE
    Neurosci Lett; 1986 Jun; 67(1):87-91. PubMed ID: 2425297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis.
    Damsma G; Biessels PT; Westerink BH; De Vries JB; Horn AS
    Eur J Pharmacol; 1988 Jan; 145(1):15-20. PubMed ID: 2832183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine.
    Gibson GE; Manger T
    Biochem Pharmacol; 1988 Nov; 37(21):4191-6. PubMed ID: 2847755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of some pharmacological properties of 4-aminopyridine and 3,4-diaminopyridine in vivo.
    Houston T; Pleuvry BJ
    Br J Anaesth; 1984 Oct; 56(10):1139-42. PubMed ID: 6148094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-performance liquid chromatographic determination of 3,4-diaminopyridine in human plasma.
    Lamiable D; Millart H; Lemeignan M; Vistelle R
    J Chromatogr; 1984 Jul; 309(1):222-4. PubMed ID: 6480771
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of 3,4-diaminopyridine and 4-aminopyridine in the anaesthetized cat.
    Durant NN; Nguyen N; Lee C; Katz RL
    Eur J Pharmacol; 1982 Oct; 84(3-4):215-9. PubMed ID: 6293848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction.
    Thomsen RH; Wilson DF
    J Pharmacol Exp Ther; 1983 Oct; 227(1):260-5. PubMed ID: 6137556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacological actions of 4-aminopyridine and two of its derivatives in the monkey.
    Biessels PT; Houwertjes MC; Agoston S; Horn AS
    Eur J Pharmacol; 1987 Mar; 135(2):155-9. PubMed ID: 3034626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtypes of K+ channels differentiated by the effect of K+ channel openers upon K+ channel blocker-induced seizures.
    Gandolfo G; Gottesmann C; Bidard JN; Lazdunski M
    Brain Res; 1989 Aug; 495(1):189-92. PubMed ID: 2550110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic facilitatory and depressant actions of 3,4-diaminopyridine: correlation with anticurare properties.
    Riker WK; Apatoff BR; Sasaki K
    Jpn J Pharmacol; 1983 Dec; 33(6):1183-9. PubMed ID: 6321834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of 3,4-diaminopyridine in bullfrog sympathetic ganglia.
    Apatoff B; Riker WK
    Brain Res; 1982 Dec; 252(2):277-86. PubMed ID: 6185176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitive trace-first liquid chromatographic determination of 4-aminopyridine in 3,4-diaminopyridine.
    Perry JA; Chang M
    J Pharm Sci; 1990 May; 79(5):437-9. PubMed ID: 2352165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacological actions of some new 4-aminopyridine derivatives.
    Biessels PT; Agoston S; Horn AS
    Eur J Pharmacol; 1984 Nov; 106(2):319-25. PubMed ID: 6529978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F.
    Siegel LS; Johnson-Winegar AD; Sellin LC
    Toxicol Appl Pharmacol; 1986 Jun; 84(2):255-63. PubMed ID: 3715874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of age-related neurochemical and behavioral deficits by 3,4-diaminopyridine.
    Peterson C; Gibson GE
    Neurobiol Aging; 1983; 4(1):25-30. PubMed ID: 6877484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 3,4-diaminopyridine and tetraethylammonium on the pre- and post-junctional alpha-adrenoceptor mediated inhibitory actions of noradrenaline in the guinea-pig ileum.
    Bauer V
    Br J Pharmacol; 1985 May; 85(1):171-7. PubMed ID: 2411318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.
    Lundh H; Nilsson O; Rosén I
    Neurology; 1984 Oct; 34(10):1324-30. PubMed ID: 6541305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.